As the market consolidates, the race is on for CROs to establish themselves as key strategic partners of pharma companies and not simply as "commodity" service providers.
from Forbes Real Time https://www.forbes.com/sites/forbestechcouncil/2017/10/23/cro-consolidation-a-sinister-threat-or-windfall-for-pharma/
via IFTTT
No comments:
Post a Comment